The role of erythrocytes and erythroid progenitor cells in tumors
In the current research context of precision treatment of malignant tumors, the advantages of immunotherapy are unmatched by conventional antitumor therapy, which can prolong progression-free survival and overall survival. The search for new targets and novel combination therapies can improve the ef...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2022-12-01
|
| Series: | Open Life Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/biol-2022-0102 |
| _version_ | 1797947699992985600 |
|---|---|
| author | Zhang Hao Wan Guang-zhi Wang Yu-ying Chen Wen Guan Jing-Zhi |
| author_facet | Zhang Hao Wan Guang-zhi Wang Yu-ying Chen Wen Guan Jing-Zhi |
| author_sort | Zhang Hao |
| collection | DOAJ |
| description | In the current research context of precision treatment of malignant tumors, the advantages of immunotherapy are unmatched by conventional antitumor therapy, which can prolong progression-free survival and overall survival. The search for new targets and novel combination therapies can improve the efficacy of immunotherapy and reduce adverse effects. Since current research targets for immunotherapy mainly focus on lymphocytes, little research has been done on erythrocytes. Nucleated erythroid precursor stem cells have been discovered to play an essential role in tumor progression. Researchers are exploring new targets and therapeutic approaches for immunotherapy from the perspective of erythroid progenitor cells (EPCs). Recent studies have shown that different subtypes of EPCs have specific surface markers and distinct biological roles in tumor immunity. CD45+ EPCs are potent myeloid-derived suppressor cell-like immunosuppressants that reduce the patient’s antitumor immune response. CD45− EPCs promote tumor invasion and metastasis by secreting artemin. A specific type of EPC also promotes angiogenesis and provides radiation protection. Therefore, EPCs may be involved in tumor growth, infiltration, and metastasis. It may also be an important cause of anti-angiogenesis and immunotherapy resistance. This review summarizes recent research advances in erythropoiesis, EPC features, and their impacts and processes on tumors. |
| first_indexed | 2024-04-10T21:31:56Z |
| format | Article |
| id | doaj.art-a65706617d8642e295874ab3de2af7ed |
| institution | Directory Open Access Journal |
| issn | 2391-5412 |
| language | English |
| last_indexed | 2024-04-10T21:31:56Z |
| publishDate | 2022-12-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Life Sciences |
| spelling | doaj.art-a65706617d8642e295874ab3de2af7ed2023-01-19T13:20:30ZengDe GruyterOpen Life Sciences2391-54122022-12-011711641165610.1515/biol-2022-0102The role of erythrocytes and erythroid progenitor cells in tumorsZhang Hao0Wan Guang-zhi1Wang Yu-ying2Chen Wen3Guan Jing-Zhi4Department of Oncology, The Fifth Medical Center, Chinese PLA (People’s Liberation Army) General Hospital, Beijing 100091, ChinaDepartment of Oncology, The Eighth Medical Center, Chinese PLA (People’s Liberation Army) General Hospital, Beijing 100071, ChinaDepartment of Oncology, First Medical Center, Chinese PLA (People’s Liberation Army) General Hospital, Beijing, ChinaDepartment of Pathology, The Eighth Medical Center, Chinese PLA (People’s Liberation Army) General Hospital, Beijing 100091, ChinaDepartment of Oncology, The Eighth Medical Center, Chinese PLA (People’s Liberation Army) General Hospital, Beijing 100071, ChinaIn the current research context of precision treatment of malignant tumors, the advantages of immunotherapy are unmatched by conventional antitumor therapy, which can prolong progression-free survival and overall survival. The search for new targets and novel combination therapies can improve the efficacy of immunotherapy and reduce adverse effects. Since current research targets for immunotherapy mainly focus on lymphocytes, little research has been done on erythrocytes. Nucleated erythroid precursor stem cells have been discovered to play an essential role in tumor progression. Researchers are exploring new targets and therapeutic approaches for immunotherapy from the perspective of erythroid progenitor cells (EPCs). Recent studies have shown that different subtypes of EPCs have specific surface markers and distinct biological roles in tumor immunity. CD45+ EPCs are potent myeloid-derived suppressor cell-like immunosuppressants that reduce the patient’s antitumor immune response. CD45− EPCs promote tumor invasion and metastasis by secreting artemin. A specific type of EPC also promotes angiogenesis and provides radiation protection. Therefore, EPCs may be involved in tumor growth, infiltration, and metastasis. It may also be an important cause of anti-angiogenesis and immunotherapy resistance. This review summarizes recent research advances in erythropoiesis, EPC features, and their impacts and processes on tumors.https://doi.org/10.1515/biol-2022-0102tumorerythroid progenitor cellsimmunotherapyanemiaepcs |
| spellingShingle | Zhang Hao Wan Guang-zhi Wang Yu-ying Chen Wen Guan Jing-Zhi The role of erythrocytes and erythroid progenitor cells in tumors Open Life Sciences tumor erythroid progenitor cells immunotherapy anemia epcs |
| title | The role of erythrocytes and erythroid progenitor cells in tumors |
| title_full | The role of erythrocytes and erythroid progenitor cells in tumors |
| title_fullStr | The role of erythrocytes and erythroid progenitor cells in tumors |
| title_full_unstemmed | The role of erythrocytes and erythroid progenitor cells in tumors |
| title_short | The role of erythrocytes and erythroid progenitor cells in tumors |
| title_sort | role of erythrocytes and erythroid progenitor cells in tumors |
| topic | tumor erythroid progenitor cells immunotherapy anemia epcs |
| url | https://doi.org/10.1515/biol-2022-0102 |
| work_keys_str_mv | AT zhanghao theroleoferythrocytesanderythroidprogenitorcellsintumors AT wanguangzhi theroleoferythrocytesanderythroidprogenitorcellsintumors AT wangyuying theroleoferythrocytesanderythroidprogenitorcellsintumors AT chenwen theroleoferythrocytesanderythroidprogenitorcellsintumors AT guanjingzhi theroleoferythrocytesanderythroidprogenitorcellsintumors AT zhanghao roleoferythrocytesanderythroidprogenitorcellsintumors AT wanguangzhi roleoferythrocytesanderythroidprogenitorcellsintumors AT wangyuying roleoferythrocytesanderythroidprogenitorcellsintumors AT chenwen roleoferythrocytesanderythroidprogenitorcellsintumors AT guanjingzhi roleoferythrocytesanderythroidprogenitorcellsintumors |